While the biotech industry continues to look for ways to push the boundaries, whether developing new science or bringing innovation into play, there are numerous challenges, including intense competition, funding and legislative hurdles. You benefit from a trusted advisor with a strong grasp of the technologies involved and the raft of services you need to protect and commercialize them.

Ranked in Tier 1 in Healthcare and Life Sciences in global directory Legal 500, Tulchinsky’s Biotech department enjoys an “impressive track record” in acting for biotech start-ups and established companies. This successful track record and talent of our lawyers ensure that we remain a prime destination for the most significant transactions in the biotech sector. We act for biotechnology companies from their establishment through growth and expansion – from the initial research phase, through financing and commercial development agreements, licensing to cooperation and commercialization agreements with large companies in Israel and abroad.

Landmark transactions include a reverse triangular merger for Orbotech, one of Israel’s leading hi-tech capital equipment producers, in the largest M&A transaction in 2018 and the third largest in recent years. In addition to Orbotech, our vast roster includes cutting-edge clients, such as National Institute for Biotechnology in the Negev, LTD. (NIBN), a unique research institute within Ben Gurion University, Teva, RedHill Biopharma, and Sanara Ventures, a healthcare innovation-investment platform providing funding and mentoring to early stage medical technology companies.

As one of Israel’s most forward-thinking, professional and cutting-edge departments, we strive to help biotech companies like yours successfully embark on ambitious corporate strategies in these challenging times.